Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis: A preliminary report

G. Paone, G. De Angelis, G. Pallotta, D. Giannarelli, A. Bisetti, F. Pigorini, F. Ameglio

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This report represents an attempt to combine the serum levels of more tumor markers together to evaluate the response to chemotherapy in 26 patients affected with small cell lung cancer (SCLC), by means of discriminant analysis. A pilot prospective study was performed on 26 subjects affected with inoperable SCLC (18 extensive diseases, and 8 limited diseases) and treated with chemotherapy (etoposide plus cisplatin regimen). Serum levels of a panel of tumor markers: Carcinoembryonic antigen (CEA), Tissue Polypeptide Antigen (TPA), Neuron Specific Enolase (NSE) and CYFRA-21.1 were determined before starting chemotherapy and at the restaging time (after 3 months). To optimize the classification power of these markers, a discriminant analysis was done, which permitted generating two classification functions, based on Tissue Polypeptide Antigen and Neuron Specific Enolase levels able to correctly classify 25 out of 26 subjects (8 progressions and 18 non progressions). The results obtained, further confirm that tumor markers are useful to evaluate the chemotherapy response and indicate a possible approach to obtain the maximum usefulness of the serum marker levels.

Original languageEnglish
Pages (from-to)140-143
Number of pages4
JournalQuarterly Journal of Nuclear Medicine
Volume39
Issue number2
Publication statusPublished - 1995

Fingerprint

Small Cell Lung Carcinoma
Discriminant Analysis
Tumor Biomarkers
Tissue Polypeptide Antigen
Drug Therapy
Phosphopyruvate Hydratase
Carcinoembryonic Antigen
Differentiation Antigens
Neoplasm Antigens
Etoposide
Serum
Cisplatin
Biomarkers
Prospective Studies

Keywords

  • canonic variable
  • discriminant analysis
  • neuron specific enolase
  • small cell lung cancer
  • tissue polypeptide antigen

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis : A preliminary report. / Paone, G.; De Angelis, G.; Pallotta, G.; Giannarelli, D.; Bisetti, A.; Pigorini, F.; Ameglio, F.

In: Quarterly Journal of Nuclear Medicine, Vol. 39, No. 2, 1995, p. 140-143.

Research output: Contribution to journalArticle

@article{9c7aa3b75b624c0bbaa5df0571968929,
title = "Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis: A preliminary report",
abstract = "This report represents an attempt to combine the serum levels of more tumor markers together to evaluate the response to chemotherapy in 26 patients affected with small cell lung cancer (SCLC), by means of discriminant analysis. A pilot prospective study was performed on 26 subjects affected with inoperable SCLC (18 extensive diseases, and 8 limited diseases) and treated with chemotherapy (etoposide plus cisplatin regimen). Serum levels of a panel of tumor markers: Carcinoembryonic antigen (CEA), Tissue Polypeptide Antigen (TPA), Neuron Specific Enolase (NSE) and CYFRA-21.1 were determined before starting chemotherapy and at the restaging time (after 3 months). To optimize the classification power of these markers, a discriminant analysis was done, which permitted generating two classification functions, based on Tissue Polypeptide Antigen and Neuron Specific Enolase levels able to correctly classify 25 out of 26 subjects (8 progressions and 18 non progressions). The results obtained, further confirm that tumor markers are useful to evaluate the chemotherapy response and indicate a possible approach to obtain the maximum usefulness of the serum marker levels.",
keywords = "canonic variable, discriminant analysis, neuron specific enolase, small cell lung cancer, tissue polypeptide antigen",
author = "G. Paone and {De Angelis}, G. and G. Pallotta and D. Giannarelli and A. Bisetti and F. Pigorini and F. Ameglio",
year = "1995",
language = "English",
volume = "39",
pages = "140--143",
journal = "Journal of Nuclear Medicine and Allied Sciences",
issn = "1124-3937",
publisher = "Minerva Medica",
number = "2",

}

TY - JOUR

T1 - Evaluation of the response to chemotherapy in patients affected with small cell lung cancer using discriminant analysis

T2 - A preliminary report

AU - Paone, G.

AU - De Angelis, G.

AU - Pallotta, G.

AU - Giannarelli, D.

AU - Bisetti, A.

AU - Pigorini, F.

AU - Ameglio, F.

PY - 1995

Y1 - 1995

N2 - This report represents an attempt to combine the serum levels of more tumor markers together to evaluate the response to chemotherapy in 26 patients affected with small cell lung cancer (SCLC), by means of discriminant analysis. A pilot prospective study was performed on 26 subjects affected with inoperable SCLC (18 extensive diseases, and 8 limited diseases) and treated with chemotherapy (etoposide plus cisplatin regimen). Serum levels of a panel of tumor markers: Carcinoembryonic antigen (CEA), Tissue Polypeptide Antigen (TPA), Neuron Specific Enolase (NSE) and CYFRA-21.1 were determined before starting chemotherapy and at the restaging time (after 3 months). To optimize the classification power of these markers, a discriminant analysis was done, which permitted generating two classification functions, based on Tissue Polypeptide Antigen and Neuron Specific Enolase levels able to correctly classify 25 out of 26 subjects (8 progressions and 18 non progressions). The results obtained, further confirm that tumor markers are useful to evaluate the chemotherapy response and indicate a possible approach to obtain the maximum usefulness of the serum marker levels.

AB - This report represents an attempt to combine the serum levels of more tumor markers together to evaluate the response to chemotherapy in 26 patients affected with small cell lung cancer (SCLC), by means of discriminant analysis. A pilot prospective study was performed on 26 subjects affected with inoperable SCLC (18 extensive diseases, and 8 limited diseases) and treated with chemotherapy (etoposide plus cisplatin regimen). Serum levels of a panel of tumor markers: Carcinoembryonic antigen (CEA), Tissue Polypeptide Antigen (TPA), Neuron Specific Enolase (NSE) and CYFRA-21.1 were determined before starting chemotherapy and at the restaging time (after 3 months). To optimize the classification power of these markers, a discriminant analysis was done, which permitted generating two classification functions, based on Tissue Polypeptide Antigen and Neuron Specific Enolase levels able to correctly classify 25 out of 26 subjects (8 progressions and 18 non progressions). The results obtained, further confirm that tumor markers are useful to evaluate the chemotherapy response and indicate a possible approach to obtain the maximum usefulness of the serum marker levels.

KW - canonic variable

KW - discriminant analysis

KW - neuron specific enolase

KW - small cell lung cancer

KW - tissue polypeptide antigen

UR - http://www.scopus.com/inward/record.url?scp=0029101347&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029101347&partnerID=8YFLogxK

M3 - Article

C2 - 8574809

AN - SCOPUS:0029101347

VL - 39

SP - 140

EP - 143

JO - Journal of Nuclear Medicine and Allied Sciences

JF - Journal of Nuclear Medicine and Allied Sciences

SN - 1124-3937

IS - 2

ER -